Chemotherapy and Radiation Therapy Increase the Risk of Stomal Lesions in Ostomy Patients
Researchers sought to determine if chemotherapy and radiation therapy increased the risk of stomal complications in ostomy patients.
All articles by Tiffany Garbutt, PhD
Vaginal Moisture Eases Adverse Effects of Pulsed Dose Rate Brachytherapy for Cervical Cancer
A quasi-experimental study sought to determine if early vaginal moisturizing eases vaginal dryness and pain associated with PDR brachytherapy for cervical cancer.
The Cost of Cancer and How Healthcare Providers Can Help Mitigate Financial Toxicity
A close-up look at the cost of cancer care, current legislative actions, and tools clinicians can use to help ease patients’ financial burden.
The Dual Role of Oncology Pharmacists in Multidisciplinary Cancer Care Teams
These cancer medication experts serve both as a resource for cancer care teams and as a liaison for patient needs.
Prevalence of Excess Body Weight-Related Cancer Varies Across the 50 US States, District of Columbia
Statistics on excess body weight-related cancers across the United States and the District of Columbia, state-by-state.
9-Week Trastuzumab Course Not Noninferior to Standard Course for HER2+ Breast Cancer, But Does Offer a Benefit
Although 9 weeks of adjuvant trastuzumab was not noninferior to the standard 1 year of trastuzumab, researchers were surprised by the difference they did find between the 2 treatment courses.
Toxicity Similar, But Overall Survival Poor in Cetuximab vs Cisplatin for HPV-Positive Oropharyngeal Cancer
In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.
Imported Doxorubicin Similar to US FDA-Approved Brand in Relapsed/Refractory Ovarian Cancer
This retrospective analysis determined the effect of Doxil vs Lipodox brands of doxorubicin, used for the treatment of recurrent or refractory ovarian cancer.
No Benefit Achieved With Cytoreductive Therapy for Essential Thrombocythemia With Nonhigh Risk of Thrombosis
A study with more than 2000 patient-years follow-up, researchers found cytoreductive therapy was not as effective in patients with ET who have lower risk for thrombosis.
Effect of ADCC Shift in Lots of Trastuzumab Could Change Its Biosimilarity to SB3
In developing a biosimilar to trastuzumab, researchers discovered a downward shift in ADCC in lots of the reference drug suggesting the 2 drugs may not be completely identical.
- Loading...
Loading...
Next post in SABCS 2018
Loading... 
Loading...